GLP-1 Collective

Policy Tracker · Patient Lens · September 18, 2026

A trial asks whether lifting weights protects muscle on tirzepatide

Muscle loss is the worry members raise most, and a Phase 4 study is finally testing the thing everyone is told to do about it.

Key details

  • A Phase 4 trial is recruiting to test whether strength training prevents muscle loss during tirzepatide treatment.
  • Amgen opened a Phase 3 trial of monthly maritide in adults with obesity who do not have type 2 diabetes.
  • Two survodutide trials opened, one on cardiovascular safety and one in MASH liver disease. The drug is not approved.
  • Other new studies are testing semaglutide for asthma control and tirzepatide for methamphetamine use disorder.

8 developments affecting GLP-1 access were tracked on Thursday, September 17, 2026, across 1 category. Each entry links to the full record.

## Research and trials

**[New drug tested alongside semaglutide for more weight loss](/fda/clinical-trial-nct07220629)**. A small early study is testing a new drug added on top of semaglutide to see if it helps people lose more weight.

**[Amgen's new obesity drug maritide in final FDA testing stage](/fda/clinical-trial-nct06858839)**. Amgen is running a large Phase 3 trial for maritide, a new obesity drug, but it is not available to patients yet.

**[New GLP-1 drug survodutide tested for scarred livers](/fda/clinical-trial-nct06632444)**. A large Phase 3 trial is now recruiting people with obesity and MASH liver disease to test a new drug called survodutide.

**[Survodutide heart safety trial finished, results coming mid-2026](/fda/clinical-trial-nct06077864)**. Survodutide is still being tested and is not available to the public yet, results are expected by mid-2026.

**[Semaglutide tested for asthma control in people with obesity](/fda/clinical-trial-nct05254314)**. A clinical trial is testing whether semaglutide (Wegovy/Ozempic) can improve asthma control in people with obesity.

**[Survodutide Phase 3 trial: what's next for this GLP-1 competitor](/fda/clinical-trial-nct07754461)**. Survodutide is still in clinical trials and is not yet approved or available as a treatment.

**[Study to test strength training and tirzepatide muscle loss](/fda/clinical-trial-nct07777575)**. A new study will test whether strength training prevents muscle loss when taking tirzepatide for weight loss.

**[Novo Nordisk's new obesity drug takes on Wegovy in 2026 trial](/fda/clinical-trial-nct07639021)**. Novo Nordisk is recruiting 230 people with obesity for a Phase 2 trial testing a new experimental drug called NNC0662-0419.

4 further items in this category were tracked today and are listed on the site.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.